Reported Saturday, argenx Plans To Submit Supplemental BLA For Efgartigimod In IMNM By End Of 2026 After Phase 3 ALKIVIA Shows 14.8-Point Greater TIS Improvement Versus Placebo At Week 52
Benzinga Newsdesk 7 hours ago
News
ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis
- ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM population
- First Phase 3 study to demonstrate statistically significant and clinically meaningful benefit in IMNM, an autoimmune myositis subtype with no approved therapies
- Consistent, clinically meaningful treatment effect in DM, demonstrating improvements in muscle strength and skin disease activity